Kristie L. Kahl is a journalist who specializes in covering oncology and cancer-related topics. She writes for various publications including CURE Media Group, OncLive, Targeted Oncology, Oncology Nursing News, and AJMC - The American Journal of Managed Care. Her work has also been featured in Urology Times and Cancer Network.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Kristie L. Kahl's articles predominantly focus on healthcare and pharmaceuticals, with an emphasis on citing data and including expert commentary. Her coverage revolves around medical research, particularly in the areas of oncology and hematological conditions.
Given her extensive use of data and reliance on expert input, pitching sources who can provide in-depth analysis or insights into new medical research findings related to cancer treatments, genetic testing advancements, or patient care would likely resonate well with Kristie.
As she does not have a specific geographic focus mentioned but covers international medical research extensively, experts from various regions contributing to global studies within these fields may find success reaching out to her.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Kristie L. Kahl
Patients with advanced renal cell carcinoma with previous exposure to lenvatinib derived modest benefit with tyrosine kinase inhibitors.
HOVON-146 showed integrating blinatumomab into pre-phase and consolidation therapy improved outcomes in newly diagnosed B-ALL.
By: Kristie L. Kahl, Darlene Dobkowski
An expert discusses recent advancements in breast cancer treatment, focusing on the addition of CDK4/6 inhibitors for high-risk ER-positive, HER2-negative breast cancer.
By: Ashley Chan, Kristie L. Kahl
Event-free survival improved with perioperative nivolumab vs neoadjuvant nivolumab plus chemotherapy in resectable NSCLC, according to a comparison of 2 trials.
By: Kristie L. Kahl
CancerNetwork co-hosts Kristie L. Kahl and Andrew Svonavec highlight abstracts to look out for surrounding the multidisciplinary approach at the upcoming ESMO Congress in Barcelona, with some additional tidbits to round out the main event.
By: Gina Mauro, Kristie L. Kahl
The phase 3 CAPItello-290 trial of capivasertib plus paclitaxel did not meet its primary end point of improved overall survival in the frontline setting of metastatic triple-negative breast cancer.
By: Kristie L. Kahl
Patients with radioiodine-refractory differentiated thyroid cancer appear to derive benefit from lenvatinib in community and academic settings.
By: Silas Inman, Kristie L. Kahl
The novel ALK inhibitor NVL-655 demonstrated encouraging activity in heavily pretreated patients with advanced ALK-positive NSCLC.
By: Silas Inman, Kristie L. Kahl
Pembrolizumab plus trastuzumab and chemotherapy reduced the risk of death by 20% in patients with advanced, unresectable, or metastatic HER2+ gastric or GEJ cancer.
By: Kristie L. Kahl, Gina Mauro
When evaluating real-world experience, differences in race/ethnicity and among elderly patients with DLBCL appeared different from those seen in clinical trials, highlighting the need for consideration in these patient populations.
(833) 317-6278 